BSP Receives US Approval for Second Patent
BSP, an Israeli start-up company developing and marketing systems for early stage non-invasive diagnosis and monitoring of ischemic heart disease through biological signal processing, announced that it has received US notification of issuance for a second patent which reinforces its original technology. BSP's flagship product, the HyperQTM stress System, enables early stage non-invasive diagnosis and monitoring of ischemic heart disease in large populations by analysis and processing of ECG signals.
The title of the patent is "Apparatus and Method for Efficient Representation of Periodic and Nearly Periodic Signals for Analysis" and its patent number is: US Patent No. 7,239,988. This patent provides a new method for displaying periodic or nearly periodic biological signals, and in particular the HyperQTM signals. The new readout method provides the clinician with an easy and efficient diagnostic tool for diagnosing ischemic heart diseases while displaying a full Stress Test results on a single page.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.